Filtered By:
Therapy: Statin Therapy

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 179 results found since Jan 2013.

Cost-benefit analysis of new lipid-lowering agents
Herz. 2022 Apr 25. doi: 10.1007/s00059-022-05116-8. Online ahead of print.ABSTRACTPatients with atherosclerotic cardiovascular disease have a high risk for subsequent cardiovascular events despite optimal drug treatment including statins and ezetimibe. Dyslipidemia represents a central and direct cause of this, with a frequent failure to achieve the target values recommended in the guidelines. New lipid-lowering substances are increasingly becoming available for treatment of this residual risk. Due to their high cost, cost-effectiveness analyses are required in order to justify their use. Important variables when consideri...
Source: Atherosclerosis - April 25, 2022 Category: Cardiology Authors: Christopher Blaum Natalie Arnold Christoph Waldeyer Source Type: research

Inclisiran: A Novel Small Interfering RNA Drug for LDL Reduction
This article is protected by copyright. All rights reserved.PMID:35279835 | DOI:10.1002/jcph.2045
Source: The Journal of Clinical Pharmacology - March 13, 2022 Category: Drugs & Pharmacology Authors: Kimberly W Smith C Michael White Source Type: research

Renoprotective Effect of KLF2 on Glomerular Endothelial Dysfunction in Hypertensive Nephropathy
Cells. 2022 Feb 22;11(5):762. doi: 10.3390/cells11050762.ABSTRACTKruppel-like factor 2 (KLF2) regulates endothelial cell metabolism; endothelial dysfunction is associated with hypertension and is a predictor of atherosclerosis development and cardiovascular events. Here, we investigated the role of KLF2 in hypertensive nephropathy by regulating KLF2 expression in human primary glomerular endothelial cells (hPGECs) and evaluating this expression in the kidney tissues of a 5/6 nephrectomy mouse model as well as patients with hypertension. Hypertension-mimicking devices and KLF2 siRNA were used to downregulate KLF2 expression...
Source: Atherosclerosis - March 10, 2022 Category: Cardiology Authors: Eunjin Bae Mi-Yeon Yu Jong-Joo Moon Ji-Eun Kim Saram Lee Sang-Woong Han Dong-Jun Park Yon-Su Kim Seung-Hee Yang Source Type: research

Inclisiran (Leqvio) for LDL-Cholesterol Lowering
Date: March 21, 2022 Issue #:  1646Summary:  The FDA has approved inclisiran (Leqvio– Novartis), a small interfering RNA (siRNA) directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA, as an adjunct to diet and maximally tolerated statin therapy for subcutaneous (SC) treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atheroscler otic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Inclisiran is the first FDA-approved PCSK9-directed siRNA therapeutic agent.
Source: The Medical Letter - February 8, 2022 Category: Drugs & Pharmacology Authors: admin Tags: alirocumab bempedoic acid evolocumab Ezetimibe Ezetrol Hypercholesterolemia inclisiran Leqvio Nexletol Nexlizet Praluent Repatha Statins Zetia Source Type: research

Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy
Biomaterials. 2021 Dec 15;280:121324. doi: 10.1016/j.biomaterials.2021.121324. Online ahead of print.ABSTRACTCardiovascular disease caused by atherosclerosis is a leading cause of morbidity and mortality worldwide. Owing to the synergistic regulation of cholesterol metabolism and lesion inflammation, the simultaneous administration of statins and nucleic acids is expected to alleviate atherosclerosis. In this work, we prepared atorvastatin- and galactose-modified trimethyl chitosan nanoparticles (GTANPs) with dual targeting to hepatocytes and lesional macrophages for encapsulating Baf60a siRNA (siBaf60a) and anti-miR-33 pD...
Source: Biomaterials - December 21, 2021 Category: Materials Science Authors: Ting Jiang Lu Xu Mengxin Zhao Fei Kong Xinrong Lu Cui Tang Chunhua Yin Source Type: research

Simvastatin  treatment promotes proliferation of human dental pulp stem cells via modulating PI3K/AKT/miR-9/KLF5 signalling pathway
J Cell Mol Med. 2021 Nov 19. doi: 10.1111/jcmm.16973. Online ahead of print.ABSTRACTSimvastatin serves as an effective therapeutic potential in the treatment of dental disease via alternating proliferation of dental pulp stem cells. First, western-blot and real-time quantitative PCR were used to detect the effect of simvastatin or LY294002 on the expression levels of AKT, miR-9 and KLF5, or determine the effect of miR-9. Simvastatin, KLF5 and AKT significantly enhanced the proliferation of pulp stem cells, whilst this effect induced by simvastatin was suppressed by LY294002, AKT siRNA, KLF5 siRNA and miR-9, and simvastatin...
Source: J Cell Mol Med - November 20, 2021 Category: Molecular Biology Authors: Jing-Hui Wang Dang-En He Source Type: research